Login to Your Account

Clinic Roundup

Tuesday, January 3, 2012
• Peregrine Pharmaceuticals Inc., of Tustin, Calif., reported preliminary data analysis from its Phase II trial in hepatitis C virus indicating that the combination of phosphatidylserine-targeting antibody bavituximab and ribavirin appeared safe and well tolerated, with patients reporting fewer side effects than in the interferon-containing arm. Initial data also indicated that both dose levels of bavituximab (0.3 mg/kg or 3 mg/kg) with ribavirin demonstrated antiviral activity; however, the antiviral effects in patients receiving the 0.3 mg/kg dosing level were more pronounced.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription